What We Have Gained from Ibogaine: α3β4 Nicotinic Acetylcholine Receptor Inhibitors as Treatments for Substance Use Disorders

Straub, Carolyn J., Rusali, Lisa E., Kremiller, Kyle M., Riley, Andrew P. · 2022 · Journal of Medicinal Chemistry

Mechanisms Review moderate

AI-extracted · unverified · confirm at source

RETROSPECTIVE ADD: Review of ibogaine and α3β4 nicotinic acetylcholine receptor inhibitors as treatments for substance use disorders.